Previous Close | 0.1301 |
Open | 0.1301 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 0.1301 - 0.1301 |
52 Week Range | 0.1260 - 0.7500 |
Volume | |
Avg. Volume | 14 |
Market Cap | 526,331 |
Beta (5Y Monthly) | 1.74 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0000 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for IDTA
IDenta Corp. (OTCQB: IDTA) is a worldwide leader in the development of Field Detection and Home Diagnostic Testing Kits for Narcotics, Explosives and Unique Forensic Products in Homeland Security and Consumer Markets. Today IDenta Corp reported its 2023 second quarter financial statement and got a GSA contract with the US government to be able to expand the activities with the USA Government's customers.
IDenta Corp. (OTCQB: IDTA) is a worldwide leader in the development of Field Detection and Home Diagnostic Testing Kits for Narcotics, Explosives and Unique Forensic Products in the Homeland Security and Consumer Markets. Today IDenta Corp reported its 2023 first quarter financial statement and continues to invest in expanding operations in the U.S. market to a variety of different sectors.
iDenta CEO Amichai Glattstein joins Proactive's Natalie Stoberman to share how the company is tackling the opioid epidemic with its forensic science based products.